AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02576093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% WOL071-007
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
Study NCT02576093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% WOL071-007
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
Study NCT02576093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0% WOL071-007
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
Study NCT02576093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of WOL071-007
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
Study NCT01960192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-MTX-Ara-C regimen
Description: high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
Study NCT01960192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FVD regimen
Description: FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
Study NCT04225806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BlueLeaf® Endovenous Valve Formation System (BlueLeaf System)
Description: The BlueLeaf System is a single-use, disposable device designed to modify the vein wall to form one or more functional autogenous valves to improve the hemodynamics of the deep venous system treated.
Study NCT03856749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote wheelchair skills training
Description: Prior to the first training session, the trainer will be provided with the results from the assessment immediately preceding training to provide him/her time to individualize the training session. Trainer will provide self-study materials (the Caregiver Handbook and caregiver-training video-recording) and an explanation on how these materials should be used.~The wheelchair user and caregiver will be trained together on wheelchair skills, using the principles of the Wheelchair Skills Training Program, as outlined in the Wheelchair Skills Program Manual using remote technology. Each training session will be with a trainer-to-dyad ratio of 1:1 1 dyad = 1 manual wheelchair user + his/her caregiver. Training will continue until the goals have been met and retained (for at least one subsequent session), using up to 4 training sessions that will each last up to 60 minutes at intervals a minimum of 3 days.
Study NCT03563586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bowel Preparation plus antibiotics
Description: Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
Study NCT03563586 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bowel Preparation
Description: Mechanical Bowel Preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm) alone Both groups will receive iv antibiotics (cefoxitin 2 gr plus metronidazole 500gr) perioperatively and discontinuation within 24 hours
Study NCT01079208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test starter infant formula
Description: infants are fed for 6 months with this starter formula
Study NCT01079208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test starter infant formula with synbiotics
Description: infant are fed for 6 months with this formula
Study NCT01079208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control standard formula
Description: infant are fed 6 months with this formula
Study NCT00811395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration
Study NCT02635139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dinner skipping
Description: 18h fasting period in the evening
Study NCT03739489 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation was a technique able to modulate the brain circuit restoring the function.
Study NCT01665079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol was administered by plasma TCI and a bolus dose was given by setting the initial plasma target between 12-16 μg/ml according to the anesthesiologist criteria. The protocol target range was selected based on previous experience using this model in the obese. After the patients reached this target, propofol infusion was stopped until the patients woke up (BIS>75). No other drugs were given during this period. Facemask ventilation was assisted only if necessary to maintain SpO2 > 90%. BIS data and propofol infusion data were automatically recorded every five seconds using the AnestFusor© program. Arterial blood samples of 4 ml for propofol assays were collected at 1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS > 75. After the patient woke up the study was considered finished and propofol infusion was restarted according to the anesthesiologist plan.
Study NCT01690559 — intervention group
Intervention type: DRUG
Intervention: Cipro (Ciprofloxacin, BAYQ3939)
Description: Patient treated with Ciproxan without dilution treatment in daily clinical practice
Study NCT02840643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bimanual hand therapy
Description: Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive bimanual hand therapy, which involves actively using both hands in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
Study NCT02840643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint therapy
Description: Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive constraint therapy, which involves actively using the impaired hand in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
Study NCT03414255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Micronized DHACM
Description: 1 mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM).
Study NCT03414255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: Injection of 1mL 0.9% Sodium Chloride Injection, USP
Study NCT03252249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 months dual anti-platelet therapy
Description: Patients with acute coronary syndrome will be randomised to 3 months dual anti-platelet therapy.
Study NCT03252249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12 months dual anti-platelet therapy
Description: Patients with acute coronary syndrome will be randomised to 12 months dual anti-platelet therapy.
Study NCT02854488 — intervention group
Intervention type: DRUG
Intervention: Yervoy
Study NCT00888329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: 40 mg administered orally with a sip of water prior to anesthesia induction.
Study NCT00888329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02051153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil (2-\[(Diphenylmethyl) sulfinyl\]acetamide (Provigil, 1997)) is a novel drug which has a demonstrable efficacy in the treatment of daytime sleepiness associated with narcolepsy (Benerjee et al., 2004). Studies on healthy volunteers show that modafinil improves neuropsychological task performance in some healthy individuals (Turner et al., 2004; Baranski et al., 2004; MÜller et al., 2004; Randall et al., 2005) and in patients with neuropsychiatric disorders (Minzenberg \& Carter, 2008).
Study NCT02051153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00811395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for teriflunomide)
Description: Film-coated tablet~Oral administration
Study NCT00811395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-β [IFN-β]
Description: Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
Study NCT00811395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-β [IFN-β]
Description: Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
Study NCT00811395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glatiramer Acetate [GA]
Description: Solution in prefilled syringe for subcutaneous injection
Study NCT00811395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate [GA]
Description: Solution in prefilled syringe for subcutaneous injection
Study NCT04170855 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Furosemide Injection
Description: We will measure kidney sodium content in patient with cardiorenal syndrome. we will inject within the week of this first measurement furosemide only in patient who will be resistant to diuretics (Based on these parameters, diuretic response will be defined as:~* A reduction in fractional spot urinary sodium~* An increase in urinary volume~* A >1 kg reduction in body weight within 24 hours from diuretic administration (extrapolation of guidance on management of acute HF) and we will do another measurement of kidney sodium content after furosemide injection.
Study NCT04095962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The MT program will be conducted for 6 months, twice a week in 60 minutes sessions. Sessions will be divided in warm-up (10 minutes, including slow walk, postural and mobility exercises for general activation, and stretching exercises), specific training (35-45 minutes, including balance/coordination training, strength and aerobic exercises) and cool down (5 minutes with breathing and stretching exercises for the main worked joints and muscles) following the main guidelines recommended by the American College of Sports Medicine \[18\] and the WHO \[19\].
Study NCT01855139 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 15 mg OD or 20 mg OD
Study NCT02092506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 day triple therapy
Description: 10 day triple therapy
Study NCT02092506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 day sequential therapy
Description: 10 day sequential therapy
Study NCT02092506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 day concomitant therapy
Description: 10 day concomitant therapy
Study NCT01962909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTP-01
Description: Dose level 1 is 10mCi (50ug of peptide)
Study NCT00779116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
Study NCT00779116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec® (cetirizine)
Description: Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
Study NCT02203916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil tablets
Study NCT02203916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azilsartan medoxomil placebo
Description: Azilsartan medoxomil placebo-matching tablets
Study NCT02729870 — intervention group
Intervention type: DRUG
Intervention: Oral Glucose Gel
Description: This group will receive the following: are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
Study NCT02729870 — intervention group
Intervention type: OTHER
Intervention: Placebo
Description: This group will receive carboxymethylcellulose (2%) oral gel. The subjects who are less than than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3-7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
Study NCT03094481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCPB
Description: Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Superficial Cervical Plexus Block at C4 or C5.
Study NCT03094481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISB
Description: Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Interscalene Brachial Plexus Block at C5 or C6.
Study NCT03094481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCPB + ISB
Description: Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided SCPB at C4 or C5 + 10ml injected for ISB at C5 or C6.
Study NCT03094481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrogen chloride , epinephrine
Description: Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine
Study NCT02295254 — intervention group
Intervention type: OTHER
Intervention: feces sample
Description: The travelers will give feces sample before and after the travel. The sample microorganisms will be analyzed.
Study NCT01832051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-trastuzumab injection
Study NCT02428387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Tools 4 Care
Description: On-line self-administered (My Tools 4 Care) transition toolkit includes interactive activities and resources to help caregivers deal with their transitions
Study NCT02177604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wingate HIT
Description: 3 sessions of Wingate based High-Intensity Interval Training (6-8 x 15 second all out sprints on a cycle ergometer interspersed by 2 minutes recovery)
Study NCT02177604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified HIT
Description: 3 sessions of Modified High-Intensity Interval Training (8 x 60 second sprints at approximately 90-95% VO2 peak on a cycle ergometer interspersed by 60 seconds recovery)
Study NCT02177604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat overfeeding
Description: 7 days of high-fat overfeeding (50% excess calories)
Study NCT02177604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-fat overfeeding
Description: 7 days of high-fat overfeeding (50% excess calories)
Study NCT03483012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a protein that affects your immune system by blocking the PD-L1 pathway
Study NCT03483012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Description: Stereotactic radiosurgery (SRS) is a standard procedure used to treat patients with cancer in the brain. SRS uses many precisely focused radiation beams to treat tumors
Study NCT04207944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulindac 400 MG
Description: Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
Study NCT04207944 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
Study NCT01375699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: As prescribed by treating provider.
Study NCT01375699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Given PO, by mouth
Study NCT04275583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3602
Description: This is a kind of proteasome inhibitor.
Study NCT01642719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks.
Study NCT01642719 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-sleep restriction
Description: Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline.
Study NCT03644316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BandGrip skin closure device
Description: topical skin closure device
Study NCT03080701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auto Mailing Plus Money
Description: Participant receives money as a thank you for completing CRC screening within 6 months.
Study NCT03080701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auto Mailing Plus Lottery
Description: Participant has a 1 in 10 chance of winning money in a lottery for completing CRC screening within 6 months.
Study NCT00696540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhalation of salbutamol diluted in hypertonic saline
Description: The first of 3 nebulizations of 0.5 mg of Salbutamol is diluted in 3.5 ml of hypertonic (3%) saline. The second and the third are diluted in normal (0.9%) saline.
Study NCT00696540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation of salbutamol diluted in normal saline
Description: The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.
Study NCT02198898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GUARDIX-SG
Study NCT02322489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent Therapy
Description: Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started and lasts for one hour.
Study NCT04448340 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: machine learning model
Description: Two classification algorithms, logistic regression and K-Nearest Neighbors (K-NNs), were investigated for their ability to predict successfully whether patients suffered from PDD or DLB.
Study NCT01513694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrumented posterolateral arthrodesis
Description: Cell suspension of mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They used a minimum dose of 0.5 x106 CSM / kg and a maximum of 1, 5x106 CSM / kg of patient weight.~Dosage Form: Suspension cell support hydroxyapatite and calcium phosphate Route of administration: placement in the fusion bed during surgery.
Study NCT03973502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DOPA PET
Description: One hour later all patient will be injected intravenously with 185 MBq (5mCi) 18F-FDOPA. PET emission data acquisition in 3-dimensional mode will be started at 60 minutes after tracer injection for 30 minutes.
Study NCT00440102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine
Study NCT00440102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: Etomidate
Study NCT04778865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D-correction
Description: Capsule with 50.000 UI cholecalciferol
Study NCT04778865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D-RDA
Description: Capsule with 4.2000 UI cholecalciferol
Study NCT00218816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nebulizer Education Intervention
Description: Asthma Education
Study NCT00218816 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Asthma Education Groups
Description: Asthma Education
Study NCT04170530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI
Description: irinotecan\* 135 mg/m² + oxaliplatin 68 mg/m² + leucovorin 400 mg/m² + 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle